Joint Centers of Excellence Program

Development and Characterization of a Novel Paclitaxel Nanoformulation for the Treatment of Multidrug Resistant Breast Cancer

The inflammation responsive materials that have been developed by our researchers have the potential to deliver drugs specifically to real inflammation sites when utilized for in vivo studies. These nanoconjugates exhibit unique responsive degradation to a broad range of reactive oxygen species (ROS). Inflammation is a hallmark of tumors including breast cancer, where these bioresponsive nanoconjugates can be applied to sense the secreting ROS and release their cargo accordingly. We aim to utilize this concept in order to develop a novel nanoformulation for the delivery of paclitaxel to treat multidrug resistant breast cancer.